There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa .
CONCLUSION BoNT-A is effective and safe in treating NDO after SCI .
There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa .
PURPOSE OnabotulinumtoxinA ( BoNT-A ) is a promising therapy for treating neurogenic detrusor overactivity ( NDO ) in individuals with spinal cord injury ( SCI ) .
This systematic review and meta- analysis aim ed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI .
Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
OBJECTIVE To assess the reliability , validity , responsiveness , and minimally important difference ( MID ) of the Incontinence Quality of Life ( I-QOL ) question naire in patients with urinary incontinence due to neurogenic detrusor overactivity . DESIGN R and omized , double-blind , multicenter , placebo-controlled study . SETTING Eight centers across Belgium , France , and Switzerl and . PARTICIPANTS Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics . Fifty-nine patients ( spinal cord injury , n=53 ; multiple sclerosis , n=6 ) were enrolled . INTERVENTION Single dose of botulinum toxin type A ( Botox ) ( 200 or 300 U ) or placebo . MAIN OUTCOME MEASURES I-QOL question naire completed at screening and over a 24-week post-treatment period . RESULTS The Cronbach alpha ranged from .79 to .93 , indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients . No item had more than 5.1 % missing or out of range values . With the exception of 2 items , questions showed acceptable item-scale correlation and scaling success results varied by domain . Post-treatment correlations indicated acceptable construct validity . The I-QOL was responsive to improvements in symptoms . MID values ranged from 4 to 11 points . CONCLUSIONS Results suggest that I-QOL is a reliable , valid , and responsive measure of incontinence-related QOL in neurogenic patients
There were no statistically significant differences between doses of 200 U and 300 U or between injections into the detrusor and submucosa .
CONCLUSION BoNT-A is effective and safe in treating NDO after SCI .
There were no statistically significant differences between doses of 200 U and 300 U or between injecting into the detrusor and submucosa .
PURPOSE OnabotulinumtoxinA ( BoNT-A ) is a promising therapy for treating neurogenic detrusor overactivity ( NDO ) in individuals with spinal cord injury ( SCI ) .
This systematic review and meta- analysis aim ed to carry out an in-depth review and to make an objective estimation of the efficacy and safety of BoNT-A on NDO after SCI .